Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel polymersomes + carboplatin + adebelimab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of paclitaxel polymersomes, carboplatin, and adebelimab, currently being evaluated as a neoadjuvant treatment for resectable mucosal melanoma. Paclitaxel polymersomes utilize a nanoparticle delivery system (polymersomes) to provide controlled release of paclitaxel, a taxane that stabilizes microtubules and inhibits mitosis. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA interstrand and intrastrand cross-links, leading to apoptosis. Adebelimab (SHR-1316) is a humanized IgG4 monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cells, thereby enhancing the immune system's ability to identify and destroy tumor cells. The regimen is being studied by Sun Yat-sen University in a Phase 2 clinical trial to assess pathological response rates in patients with resectable mucosal melanoma.
- Brand names
- Adely
- Other names
- Paclitaxel Polymersomes for InjectionSHR-1316SHR1316SHR 1316
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on paclitaxel polymersomes + carboplatin + adebelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel polymersomes + carboplatin + adebelimab.